SAIDs are a growing number of rare conditions (monogenic or multifactorial), secondary to disregulation of mechanisms controlling innate immune responses and characterized by sterile inflammation.
For monogenic SAID, personalised medicine is already a consolidated reality; however new evidence suggests that even undefined SAID could benefit from this approach.
The PerSAIDs Project aims to:
-link together the larger SAID registries in Europe, developing specific AI strategies to maximize the use of existing repositories;
-analyse available data and produce new omics, exploiting biological samples from the biobank;
-generate standardized bioinformatic protocols for data management and analysis;
-develop appropriate tools to decode the disease complexity in clinical practise;
-improve SAID classification, diagnosis and prognosis, supporting the development of novel therapies.
An innovative AI approach could really impact on patients’ quality of life.
